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Abstract
The	formylpeptide	receptors	(nomenclature	agreed	by	the	NC-IUPHAR	Subcommittee	on	the
formylpeptide	receptor	family	[196])	respond	to	exogenous	ligands	such	as	the	bacterial	product
fMet-Leu-Phe	(fMLP)	and	endogenous	ligands	such	as	lipoxin	A4	(LXA4),	15-epi-lipoxin	A4,	annexin	I	,
cathepsin	G,	amyloid	β42,	serum	amyloid	A	and	spinorphin,	derived	from	β-haemoglobin.	FPR1	also
serves	as	a	plague	receptor	for	selective	destruction	of	human	immune	cells	by	Y.	pestis	[135].	The
FPR1/2	agonists	'compound	17b'	and	'compound	43'	have	shown	cardiac	protective	functions	[149,
64].
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